Inside USP: Characterization of Heparin Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside USP: Characterization of Heparin Products
USP workshop participants support new methods to safeguard heparin products but desire international harmonization. This article contains bonus online-exclusive material.


Pharmaceutical Technology
Volume 33, Issue 10

Conclusions

Regulatory expectations regarding the quality of UFH have increased since the global heparin crisis of 2008. Industry has witnessed modernization of pharmacopeial methods that demand higher criteria for all quality attributes. Orthogonal tests have been implemented to identify heparin and to demonstrate lack of contaminants. At the workshop, USP and FDA jointly announced their intent to further revise heparin monographs to ensure the continued supply of safe and effectve heparin for patients. USP will update heparin stakeholders about the status of the monograph revisions and will ensure sufficient time for a public evaluation of the procedures, specifications, and implementation date.

Anita Y. Szajek, PhD, is a senior scientific liaison, Tina S. Morris, PhD, is vice-president of biologics & biotechnology, both at the US Pharmacopeia, 12601 Twinbrook Parkway, Rockville, MD 20852-1790, tel. 301.816.8325,

References

1. USP Heparin Hot Topics Page, http://www.usp.org/hottopics/heparin.html, accessed Aug. 27, 2009.

2. USP Heparin Workshop Page, http://www.usp.org/meetings/workshops/heparinWorkshop2009.html, accessed Aug. 27, 2009.

3. FDA, Information on Heparin (2009), http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM112597, accessed Aug. 27, 2009.

4. M. Guerrini et al., "Oversulfated Chondroitin Sulfate Is a Contaminant in Heparin Associated with Adverse Clinical Events," Nature Biotechnol. 26 (6), 669–675 (2008).

5. EMEA, Guideline on Similar Biological Medicinal Products Containing Low-Molecular-Weight-Heparins (London, March 2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here